Chief Executive Officer, Isogenica

Dr Sceats joined Isogenica as Chief Executive Officer in September 2018 leading a new strategy to focus on bispecifics discovery and development based on the company’s established LlamdA® synthetic single domain (VHH) library.

Before joining Isogenica, Emma was CEO of CN Bio Innovations, which she grew from a Oxford University spin-out to a recognised leader in human Organ-on-Chip technologies. She was instrumental in the development and execution of CN Bio’s vision, resulting in strong revenue growth, rapid development of two innovative new products, and a pioneering partnership with the Food and Drug Administration to characterise the use of Organs-on-Chips in drug development and regulatory evaluation.

Emma was an inaugural winner in 2016 of Innovate UK’s Women in Innovation award. Earlier in her career, Emma worked at Oxford University Innovation patenting, marketing and licensing technologies and creating spin-out companies to exploit IP developed at the university. Emma was a Presidential scholar in Chemistry at the Massachusetts Institute of Technology and a graduate scholar at the University of Oxford.


17 November 2020